In this study, we hypothesize that multi‐omics testing, using both ctDNA as well as protein tumor biomarker S100B, may be beneficial as a prognostic biomarker of melanoma recurrence after surgery in early‐stage patients (stages 0—III, 48% in stages 0—IIA). Here, S100B is linked to melanoma.